Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2010 consensus guidelines for definitive external beam radiotherapy for prostate carcinoma.
Hayden AJ, Martin JM, Kneebone AB, Lehman M, Wiltshire KL, Skala M, Christie D, Vial P, McDowall R, Tai KH; Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group. Hayden AJ, et al. Among authors: wiltshire kl. J Med Imaging Radiat Oncol. 2010 Dec;54(6):513-25. doi: 10.1111/j.1754-9485.2010.02214.x. J Med Imaging Radiat Oncol. 2010. PMID: 21199428
Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladder.
Hindson BR, Turner SL, Millar JL, Foroudi F, Gogna NK, Skala M, Kneebone A, Christie DR, Lehman M, Wiltshire KL, Tai KH; RANZCR Faculty of Radiation Oncology Genito-Urinary Group (FROGG). Hindson BR, et al. J Med Imaging Radiat Oncol. 2012 Feb;56(1):18-30. doi: 10.1111/j.1754-9485.2011.02336.x. J Med Imaging Radiat Oncol. 2012. PMID: 22339742
A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.
Pearse M, Fraser-Browne C, Davis ID, Duchesne GM, Fisher R, Frydenberg M, Haworth A, Jose C, Joseph DJ, Lim TS, Matthews J, Millar J, Sidhom M, Spry NA, Tang CI, Turner S, Williams SG, Wiltshire K, Woo HH, Kneebone A. Pearse M, et al. Among authors: wiltshire k. BJU Int. 2014 Mar;113 Suppl 2:7-12. doi: 10.1111/bju.12623. BJU Int. 2014. PMID: 24894850 Clinical Trial.
Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group.
Lieng H, Hayden AJ, Christie DRH, Davis BJ, Eade TN, Emmett L, Holt T, Hruby G, Pryor D, Shakespeare TP, Sidhom M, Skala M, Wiltshire K, Yaxley J, Kneebone A. Lieng H, et al. Among authors: wiltshire k. Radiother Oncol. 2018 Nov;129(2):377-386. doi: 10.1016/j.radonc.2018.06.027. Epub 2018 Jul 20. Radiother Oncol. 2018. PMID: 30037499
Contour variation is a primary source of error when delivering post prostatectomy radiotherapy: Results of the Trans-Tasman Radiation Oncology Group 08.03 Radiotherapy Adjuvant Versus Early Salvage (RAVES) benchmarking exercise.
Cloak K, Jameson MG, Paneghel A, Wiltshire K, Kneebone A, Pearse M, Sidhom M, Tang C, Fraser-Browne C, Holloway LC, Haworth A. Cloak K, et al. Among authors: wiltshire k. J Med Imaging Radiat Oncol. 2019 Jun;63(3):390-398. doi: 10.1111/1754-9485.12884. Epub 2019 Apr 5. J Med Imaging Radiat Oncol. 2019. PMID: 30950223
89 results